Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation.
暂无分享,去创建一个
George Loizou | Melvin E Andersen | Hugh A Barton | Yu-Mei Tan | Nancy Jones | Martin Spendiff | Gunnar Johanson | Weihsueh A Chiu | A John Bailer | Frédéric Y Bois | Sean Hays | Christopher J Portier | R Woodrow Setzer | Robert S Dewoskin | Robert C Macphail | M. Andersen | F. Bois | C. Portier | R. Setzer | A. J. Bailer | G. Loizou | W. Chiu | S. Hays | Y. Tan | H. Barton | G. Johanson | R. Macphail | M. Spendiff | R. Dewoskin | Nancy Jones | R. Woodrow Setzer
[1] Stefano Tarantola,et al. Sensitivity Analysis as an Ingredient of Modeling , 2000 .
[2] R C Spear,et al. Mechanisms of benzene carcinogenesis: application of a physiological model of benzene pharmacokinetics and metabolism. , 1991, Toxicology letters.
[3] F. A. Smith,et al. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. , 1987, Toxicology and applied pharmacology.
[4] Harvey J Clewell,et al. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.
[5] Melvin E. Andersen,et al. Gas Uptake Inhalation Techniques and the Rates of Metabolism of Chloromethanes, Chloroethanes, and Chloroethylenes in the Rat , 1990 .
[6] W Thormann,et al. Antinociceptive effects, metabolism and disposition of ketamine in ponies under target-controlled drug infusion. , 2006, Toxicology and applied pharmacology.
[7] Malcolm Rowland,et al. Lumping of Whole-Body Physiologically Based Pharmacokinetic Models , 1998, Journal of Pharmacokinetics and Biopharmaceutics.
[8] Richard D. Thomas. Drinking Water and Health , 1986 .
[9] Frédéric Y. Bois,et al. Assessing the reliability of PBPK models using data from methyl chloride-exposed, non-conjugating human subjects , 2001, Archives of Toxicology.
[10] N. Singpurwalla,et al. Membership Functions and Probability Measures of Fuzzy Sets , 2004 .
[11] Michael A. Gallo,et al. Reconstruction of short-term multi-route exposure to volatile organic compounds using physiologically based pharmacokinetic models , 1994 .
[12] K. Bischoff,et al. Methotrexate pharmacokinetics. , 1971, Journal of pharmaceutical sciences.
[13] Joseph G. Ibrahim,et al. A Bayesian compartmental model for the evaluation of 1,3‐butadiene metabolism , 2003 .
[14] G. Casella,et al. Statistical Inference , 2003, Encyclopedia of Social Network Analysis and Mining.
[15] Thomas J. Smith,et al. Development of a physiologically based toxicokinetic model for butadiene and four major metabolites in humans: global sensitivity analysis for experimental design issues. , 2007, Chemico-biological interactions.
[16] R. Coulombe,et al. Pharmacokinetics in Risk Assessment , 1996 .
[17] M C Kohn,et al. A physiologically based pharmacokinetic model for inhalation and intravenous administration of naphthalene in rats and mice. , 2001, Toxicology and applied pharmacology.
[18] Walter Schmitt,et al. Development and Evaluation of a Generic Physiologically Based Pharmacokinetic Model for Children , 2006, Clinical pharmacokinetics.
[19] Malcolm Rowland,et al. Fuzzy Simulation of Pharmacokinetic Models: Case Study of Whole Body Physiologically Based Model of Diazepam , 2004, Journal of Pharmacokinetics and Pharmacodynamics.
[20] Walter Schmitt,et al. Development of a Physiology-Based Whole-Body Population Model for Assessing the Influence of Individual Variability on the Pharmacokinetics of Drugs , 2007, Journal of Pharmacokinetics and Pharmacodynamics.
[21] A Gelman,et al. Optimal design for a study of butadiene toxicokinetics in humans. , 1999, Toxicological sciences : an official journal of the Society of Toxicology.
[22] R H Reitz,et al. Non-linear pharmacokinetic parameters need to be considered in high dose/low dose extrapolation. , 1980, Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement.
[23] Gunnar Johanson,et al. A human physiological model describing acetone kinetics in blood and breath during various levels of physical exercise. , 2006, Toxicology letters.
[24] J. C. Helton,et al. An Investigation of Uncertainty and Sensitivity Analysis Techniques for Computer Models , 1988 .
[25] James J. Buckley. Decision Making Under Risk: A Comparison of Bayesian and Fuzzy Set Methods , 1983 .
[26] Fredrik U. Jönsson,et al. Physiologically based pharmacokinetic modeling of inhalation exposure of humans to dichloromethane during moderate to heavy exercise. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.
[27] H J Clewell,et al. Incorporation of pharmacokinetics in noncancer risk assessment: example with chloropentafluorobenzene. , 1994, Risk analysis : an official publication of the Society for Risk Analysis.
[28] G. Johanson,et al. Spreadsheet programming--a new approach in physiologically based modeling of solvent toxicokinetics. , 1988, Toxicology letters.
[29] J. G. Kalbfleisch. Probability and Statistical Inference , 1977 .
[30] C DeRosa,et al. Using structural information to create physiologically based pharmacokinetic models for all polychlorinated biphenyls. , 1997, Toxicology and applied pharmacology.
[31] A. Gelman,et al. Physiological Pharmacokinetic Analysis Using Population Modeling and Informative Prior Distributions , 1996 .
[32] P. Müller. Simulation Based Optimal Design , 2005 .
[33] A. Saltelli,et al. Sensitivity Anaysis as an Ingredient of Modeling , 2000 .
[34] Aldo Rescigno,et al. The use and abuse of models , 1987, Journal of Pharmacokinetics and Biopharmaceutics.
[35] H. B. Matthews,et al. Using Structural Information to Create Physiologically Based Pharmacokinetic Models for All Polychlorinated Biphenyls: I. Tissue:Blood Partition Coefficients , 1997 .
[36] H J Clewell,et al. Applying simulation modeling to problems in toxicology and risk assessment--a short perspective. , 1995, Toxicology and applied pharmacology.
[37] Hugh A Barton,et al. Framework for Evaluation of Physiologically‐Based Pharmacokinetic Models for Use in Safety or Risk Assessment , 2004, Risk analysis : an official publication of the Society for Risk Analysis.
[38] P. J. Green,et al. Probability and Statistical Inference , 1978 .
[39] D J Paustenbach,et al. A physiological pharmacokinetic description of the tissue distribution and enzyme-inducing properties of 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat. , 1990, Toxicology and applied pharmacology.
[40] L. Stark,et al. Three algorithms for interpreting models consisting of ordinary differential equations: Sensitivity coefficients, sensitivity functions, global optimization , 1982 .
[41] Malcolm Rowland,et al. Reducing Whole Body Physiologically Based Pharmacokinetic Models Using Global Sensitivity Analysis: Diazepam Case Study , 2006, Journal of Pharmacokinetics and Pharmacodynamics.
[42] M C Kohn,et al. Effects of the structure of a toxicokinetic model of butadiene inhalation exposure on computed production of carcinogenic intermediates. , 1996, Toxicology.
[43] M E Andersen,et al. Physiological modeling reveals novel pharmacokinetic behavior for inhaled octamethylcyclotetrasiloxane in rats. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.